Houston, Texas 77030


This trial studies how well self-administered meditation therapy works in improving anxiety and depression in cancer patients who exhibit psychosocial distress. Meditation therapy is a mind-body approach that uses a variety of techniques, such as deep breathing, sound, or movement, that may help to decrease distress and anxiety and enhance the health and quality of life of patients with cancer.

Study summary:

PRIMARY OBJECTIVES: I. To determine the feasibility of having patients self-administer meditation recordings using a portable, computer-based program during a 2-week period. SECONDARY OBJECTIVES: I. Assess the effect of self-administered meditation on anxiety, depression and other symptoms that are part of the Edmonton Symptom Assessment Scale (ESAS) questionnaire. II. Evaluate participant satisfaction with the meditation delivery and tracking program. III. Examine the association between the frequency of practice (number of sessions a day) and choice of length of practice (5, 10, or 15 minute sessions) and anxiety, depression and other patient reported outcomes. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I (MEDITATION): Patients watch a pre-recorded instructional meditation video via an iPod meditation app. Patients then complete meditation exercises using the meditation app over 5-15 minutes once daily (QD) for up to 2 weeks. Patients also complete questionnaires before and after meditation sessions and participate in an interview over 10 minutes. GROUP II (WAITLIST CONTROL): Patients receive supportive care, such as access to social workers, support groups, spiritual care, or other patient services for up to 2 weeks. Patients also complete questionnaires over 15-20 minutes and participate in an interview over 10 minutes.


Inclusion Criteria: - Patients at MD Anderson with a cancer history who are either undergoing active treatment or who have completed treatment for their cancer - Must understand and read English, sign a written informed consent, and follow protocol requirements - Willing to come to MD Anderson Main Campus (Texas Medical Center) for enrollment - Patient self-reported ESAS psychological scale score (sum of anxiety and depression scores) between 4 and 11 (and/or) individual anxiety or depression score between 4 and 7 on a 0 to 10 numeric scale, where 10 is the worst possible - If on medication for anxiety, stable dose of medications for management of anxiety symptoms for at least six weeks prior to enrollment with no plans to change meditations in the subsequent four weeks. Increases or decreases allowed within drug class, but changing drug class will make patient in-evaluable Exclusion Criteria: - Diagnosis of a formal thought disorder (e.g., schizophrenia) - Known history of a neurological and/or psychological disorder that in the physician's opinion may interfere with the patient's ability to cooperate with study procedures



Primary Contact:

Principal Investigator
Gabriel Lopez
M.D. Anderson Cancer Center

Gabriel Lopez, MD
Phone: 713-792-5105
Email: glopez@mdanderson.org

Backup Contact:


Location Contact:

Houston, Texas 77030
United States

Gabriel Lopez-Berestein
Phone: 713-792-5105

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.